Dr. Ahmed is originally from Egypt and received his bachelor of pharmaceutical sciences in Egypt in 2005. He decided to pursue his PhD in medicinal chemistry at South Dakota State University starting from 2009 until 2014. During his PhD, he had the opportunity to integrate the concepts of organic chemistry along with computational simulations coupled with biological screening to tackle molecular targets affiliated with melanoma. He conducted industrial postdoctoral training at Kemin Industries in Des Moines, Iowa for a year. Following that, he accepted an assistant professor position at the school of pharmacy at the British University in Egypt where he conducted multiple research activities related to in silico drug repositioning and design / synthesis of new chemical entities targeting breast cancer, hepatocellular carcinoma, melanoma, and leukemia. He also managed to attract funding nationally before he decided to drive his research towards coupling medicinal chemistry along with cardiomyocytes regeneration. Dr. Ahmed decided to join UTSW where he can offer new translational approaches targeting cardiac affiliated problems. Dr. Ahmed’s current research activities are focusing on offering new chemical entities towards reversal of DNA damage and cardiomyocytes regeneration.

Research Interest

  • Computational Chemistry
  • Drug Discovery
  • Medicinal Chemistry
  • Regenerative Medicine


Featured Publications LegendFeatured Publications

Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular carcinoma.
Ayoub BM, Attia YM, Ahmed MS J Enzyme Inhib Med Chem 2018 Dec 33 1 858-866
Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
Ismail RSM, Abou-Seri SM, Eldehna WM, Ismail NSM, Elgazwi SM, Ghabbour HA, Ahmed MS, Halaweish FT, Abou El Ella DA Eur J Med Chem 2018 Jul 155 782-796
Design, synthesis, and biological evaluation of novel amide and hydrazide based thioether analogs targeting Histone deacteylase (HDAC) enzymes.
Farag AB, Ewida HA, Ahmed MS Eur J Med Chem 2018 Mar 148 73-85
Biological screening of cucurbitacin inspired estrone analogs targeting mitogen-activated protein kinase (MAPK) pathway.
Ahmed MS, El-Senduny F, Taylor J, Halaweish FT Chem Biol Drug Des 2017 Sep 90 3 478-484
Structural optimization and biological screening of a steroidal scaffold possessing cucurbitacin-like functionalities as B-Raf inhibitors.
Ahmed MS, Kopel LC, Halaweish FT ChemMedChem 2014 Jul 9 7 1361-7
Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma.
Ahmed MS, Halaweish FT J Enzyme Inhib Med Chem 2014 Apr 29 2 162-7
Synthesis of novel estrone analogs by incorporation of thiophenols via conjugate addition to an enone side chain.
Kopel LC, Ahmed MS, Halaweish FT Steroids 2013 Nov 78 11 1119-25

Honors & Awards

  • Travel Grant Award
    American Chemical Society (2014)
  • Louge Graduate Research Excellence Award
    South Dakota State University (2013)
  • Haskett Graduate Teaching Excellence Award
    South Dakota State University (2012)

Professional Associations/Affiliations

  • American Chemical Society (2009)